B. Lueza

1.5k total citations · 1 hit paper
20 papers, 790 citations indexed

About

B. Lueza is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, B. Lueza has authored 20 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Economics and Econometrics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in B. Lueza's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Lung Cancer Treatments and Mutations (4 papers) and Economic and Financial Impacts of Cancer (3 papers). B. Lueza is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Lung Cancer Treatments and Mutations (4 papers) and Economic and Financial Impacts of Cancer (3 papers). B. Lueza collaborates with scholars based in France, United States and United Kingdom. B. Lueza's co-authors include Jean‐Pierre Pignon, Jean-Yves Douillard, Marc Peeters, Heinz‐Josef Lenz, Josep Tabernero, Alan P. Venook, Dirk Arnold, Andrés Cervantes, Eric Van Cutsem and Volker Heinemann and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

B. Lueza

18 papers receiving 774 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

2017 554 citations Dirk Arnold, B. Lueza et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Lueza France	10	595	302	234	152	143	20	790
Seta Shahin United States	8	812 1.4×	319 1.1×	145 0.6×	110 0.7×	186 1.3×	13	948
Roger Sidhu United States	13	715 1.2×	388 1.3×	248 1.1×	156 1.0×	152 1.1×	29	904
Alberto F. Sobrero Italy	15	578 1.0×	224 0.7×	151 0.6×	130 0.9×	92 0.6×	66	697
Clemens Gießen Germany	20	944 1.6×	548 1.8×	271 1.2×	252 1.7×	288 2.0×	46	1.1k
Christian Lerchenmüller Germany	16	582 1.0×	417 1.4×	195 0.8×	135 0.9×	128 0.9×	49	890
Lothar Müller Germany	13	424 0.7×	269 0.9×	96 0.4×	99 0.7×	86 0.6×	71	850
C. Barone Italy	7	516 0.9×	223 0.7×	165 0.7×	179 1.2×	89 0.6×	19	682
Tae Won Kim South Korea	8	616 1.0×	258 0.9×	175 0.7×	110 0.7×	169 1.2×	17	699
Christopher Hagenstad United States	8	687 1.2×	297 1.0×	149 0.6×	103 0.7×	198 1.4×	14	847
Katrina S. Pedersen United States	15	661 1.1×	220 0.7×	149 0.6×	293 1.9×	65 0.5×	73	970

Countries citing papers authored by B. Lueza

Since Specialization

Citations

This map shows the geographic impact of B. Lueza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Lueza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Lueza more than expected).

Fields of papers citing papers by B. Lueza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Lueza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Lueza. The network helps show where B. Lueza may publish in the future.

Co-authorship network of co-authors of B. Lueza

This figure shows the co-authorship network connecting the top 25 collaborators of B. Lueza. A scholar is included among the top collaborators of B. Lueza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Lueza. B. Lueza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tchétché, Didier, et al.. (2023). Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial. The European Journal of Health Economics. 25(3). 447–457. 2 indexed citations

Lueza, B., Anne Aupérin, Charlotte Rigaud, et al.. (2023). Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma. The European Journal of Health Economics. 25(2). 307–317. 2 indexed citations

Lueza, B., et al.. (2023). RWD142 Global Use of Nordic Real-World Evidence: A Systematic Review of Published Literature and HTA Submissions. Value in Health. 26(12). S531–S531.

Lueza, B., et al.. (2020). S0463 Economic Costs Associated With Reduction in Work Productivity Loss for Ulcerative Colitis Patients Receiving Ustekinumab Using Results From the UNIFI Clinical Trial. The American Journal of Gastroenterology. 115(1). S233–S233. 1 indexed citations

Teeple, Amanda, et al.. (2020). S0464 Cost Reduction Associated With Improvement in Work Productivity Loss From Ustekinumab Treatment by Disease Severity States in Crohn's Disease Patients: Results From the IM-UNITI Clinical Trial. The American Journal of Gastroenterology. 115(1). S233–S233. 1 indexed citations

Petit, Claire, Pierre Blanchard, Jean‐Pierre Pignon, & B. Lueza. (2019). Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas. Systematic Reviews. 8(1). 96–96. 11 indexed citations

Charrier, Mélinda, Laura Mezquita, B. Lueza, et al.. (2019). Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients. European Journal of Cancer. 108. 88–96. 34 indexed citations

Lueza, B., et al.. (2019). PCN205 COMPARISON OF METHODS TO ACCOUNT FOR CURED PATIENTS IN A COST-EFFECTIVENESS ANALYSIS: A CASE STUDY IN ONCOLOGY. Value in Health. 22. S475–S475. 1 indexed citations

Costa, Nilza, Julia Bonastre, B. Dervaux, et al.. (2018). Sources de données, données utilisées et modalité de recueil. Revue d Épidémiologie et de Santé Publique. 66. S73–S91. 3 indexed citations

10.

Seymour, Lesley, Gwénaël Le Teuff, Élisabeth Brambilla, et al.. (2018). LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer. Clinical Lung Cancer. 20(2). 66–73.e6. 19 indexed citations

11.

Mezquita, Laura, Mélinda Charrier, Laura Faivre, et al.. (2017). Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 112. 10–15. 4 indexed citations

12.

Arnold, Dirk, B. Lueza, Jean-Yves Douillard, et al.. (2017). Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Annals of Oncology. 28(8). 1713–1729. 554 indexed citations breakdown →

13.

Lueza, B., et al.. (2016). Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study. PLoS ONE. 11(3). e0150032–e0150032. 15 indexed citations

14.

Lueza, B., Federico Rotolo, Julia Bonastre, Jean‐Pierre Pignon, & Stefan Michiels. (2016). Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Medical Research Methodology. 16(1). 37–37. 28 indexed citations

15.

Guyot, Patricia, et al.. (2016). Extrapolation of Survival Curves from Cancer Trials Using External Information. Medical Decision Making. 37(4). 353–366. 51 indexed citations

16.

Bonastre, Julia, et al.. (2015). How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models. Value in Health. 18(7). A704–A704. 17 indexed citations

17.

Bonastre, Julia, Sophie Marguet, B. Lueza, et al.. (2014). Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer. Journal of Clinical Oncology. 32(31). 3513–3519. 21 indexed citations

18.

Ramaekers, Bram, Manuela Joore, B. Lueza, et al.. (2013). Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients. Journal of Thoracic Oncology. 8(10). 1295–1307. 16 indexed citations

19.

Ruysscher, Dirk De, Bram Ramaekers, B. Lueza, et al.. (2012). Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small Cell Lung Cancer Patients: A Cost-Effectiveness Analysis. Annals of Oncology. 23. ix397–ix397. 1 indexed citations

20.

Auger, Nathalie, B. Lueza, Frédéric Commo, et al.. (2012). ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report.. Journal of Clinical Oncology. 30(15_suppl). 10556–10556. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact